Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver

Squalene synthase (SS) catalyzes the biosynthesis of squalene, the first specific intermediate in the cholesterol biosynthetic pathway. To test the feasibility of lowering plasma cholesterol by inhibiting hepatic SS, we generated mice in which SS is specifically knocked out in the liver (L-SSKO) usi...

Full description

Bibliographic Details
Main Authors: Shuichi Nagashima, Hiroaki Yagyu, Ryuichi Tozawa, Fumiko Tazoe, Manabu Takahashi, Tetsuya Kitamine, Daisuke Yamamuro, Kent Sakai, Motohiro Sekiya, Hiroaki Okazaki, Jun-ichi Osuga, Akira Honda, Shun Ishibashi
Format: Article
Language:English
Published: Elsevier 2015-05-01
Series:Journal of Lipid Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520312396
id doaj-7b48d2ba7b554bd8aaf864108108d737
record_format Article
spelling doaj-7b48d2ba7b554bd8aaf864108108d7372021-04-28T05:57:18ZengElsevierJournal of Lipid Research0022-22752015-05-015659981005Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liverShuichi Nagashima0Hiroaki Yagyu1Ryuichi Tozawa2Fumiko Tazoe3Manabu Takahashi4Tetsuya Kitamine5Daisuke Yamamuro6Kent Sakai7Motohiro Sekiya8Hiroaki Okazaki9Jun-ichi Osuga10Akira Honda11Shun Ishibashi12Division of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanDivision of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanDepartment of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, JapanDivision of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanDivision of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanDepartment of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, JapanDivision of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanDivision of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanDepartment of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, JapanDepartment of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, JapanDivision of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanJoint Research Center, Tokyo Medical University Ibaraki Medical Center, Ibaraki 300-0395, JapanTo whom correspondence should be addressed.; Division of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan; To whom correspondence should be addressed.Squalene synthase (SS) catalyzes the biosynthesis of squalene, the first specific intermediate in the cholesterol biosynthetic pathway. To test the feasibility of lowering plasma cholesterol by inhibiting hepatic SS, we generated mice in which SS is specifically knocked out in the liver (L-SSKO) using Cre-loxP technology. Hepatic SS activity of L-SSKO mice was reduced by >90%. In addition, cholesterol biosynthesis in the liver slices was almost eliminated. Although the hepatic squalene contents were markedly reduced in L-SSKO mice, the hepatic contents of cholesterol and its precursors distal to squalene were indistinguishable from those of control mice, indicating the presence of sufficient centripetal flow of cholesterol and/or its precursors from the extrahepatic tissues. L-SSKO mice showed a transient liver dysfunction with moderate hepatomegaly presumably secondary to increased farnesol production. In a fed state, the plasma total cholesterol and triglyceride were significantly reduced in L-SSKO mice, primarily owing to reduced hepatic VLDL secretion. In a fasted state, the hypolipidemic effect was lost. mRNA expression of liver X receptor α target genes was reduced, while that of sterol-regulatory element binding protein 2 target genes was increased. In conclusion, liver-specific ablation of SS inhibits hepatic cholesterol biosynthesis and induces hypolipidemia without increasing significant mortality.http://www.sciencedirect.com/science/article/pii/S0022227520312396cholesterol/biosynthesisenzymology/enzyme regulationlipoproteins/metabolismvery low density lipoproteininborn errors of metabolismCre recombinase
collection DOAJ
language English
format Article
sources DOAJ
author Shuichi Nagashima
Hiroaki Yagyu
Ryuichi Tozawa
Fumiko Tazoe
Manabu Takahashi
Tetsuya Kitamine
Daisuke Yamamuro
Kent Sakai
Motohiro Sekiya
Hiroaki Okazaki
Jun-ichi Osuga
Akira Honda
Shun Ishibashi
spellingShingle Shuichi Nagashima
Hiroaki Yagyu
Ryuichi Tozawa
Fumiko Tazoe
Manabu Takahashi
Tetsuya Kitamine
Daisuke Yamamuro
Kent Sakai
Motohiro Sekiya
Hiroaki Okazaki
Jun-ichi Osuga
Akira Honda
Shun Ishibashi
Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver
Journal of Lipid Research
cholesterol/biosynthesis
enzymology/enzyme regulation
lipoproteins/metabolism
very low density lipoprotein
inborn errors of metabolism
Cre recombinase
author_facet Shuichi Nagashima
Hiroaki Yagyu
Ryuichi Tozawa
Fumiko Tazoe
Manabu Takahashi
Tetsuya Kitamine
Daisuke Yamamuro
Kent Sakai
Motohiro Sekiya
Hiroaki Okazaki
Jun-ichi Osuga
Akira Honda
Shun Ishibashi
author_sort Shuichi Nagashima
title Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver
title_short Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver
title_full Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver
title_fullStr Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver
title_full_unstemmed Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver
title_sort plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 2015-05-01
description Squalene synthase (SS) catalyzes the biosynthesis of squalene, the first specific intermediate in the cholesterol biosynthetic pathway. To test the feasibility of lowering plasma cholesterol by inhibiting hepatic SS, we generated mice in which SS is specifically knocked out in the liver (L-SSKO) using Cre-loxP technology. Hepatic SS activity of L-SSKO mice was reduced by >90%. In addition, cholesterol biosynthesis in the liver slices was almost eliminated. Although the hepatic squalene contents were markedly reduced in L-SSKO mice, the hepatic contents of cholesterol and its precursors distal to squalene were indistinguishable from those of control mice, indicating the presence of sufficient centripetal flow of cholesterol and/or its precursors from the extrahepatic tissues. L-SSKO mice showed a transient liver dysfunction with moderate hepatomegaly presumably secondary to increased farnesol production. In a fed state, the plasma total cholesterol and triglyceride were significantly reduced in L-SSKO mice, primarily owing to reduced hepatic VLDL secretion. In a fasted state, the hypolipidemic effect was lost. mRNA expression of liver X receptor α target genes was reduced, while that of sterol-regulatory element binding protein 2 target genes was increased. In conclusion, liver-specific ablation of SS inhibits hepatic cholesterol biosynthesis and induces hypolipidemia without increasing significant mortality.
topic cholesterol/biosynthesis
enzymology/enzyme regulation
lipoproteins/metabolism
very low density lipoprotein
inborn errors of metabolism
Cre recombinase
url http://www.sciencedirect.com/science/article/pii/S0022227520312396
work_keys_str_mv AT shuichinagashima plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
AT hiroakiyagyu plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
AT ryuichitozawa plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
AT fumikotazoe plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
AT manabutakahashi plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
AT tetsuyakitamine plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
AT daisukeyamamuro plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
AT kentsakai plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
AT motohirosekiya plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
AT hiroakiokazaki plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
AT junichiosuga plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
AT akirahonda plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
AT shunishibashi plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver
_version_ 1721504851501776896